61542-10-7

Usage

Appearance

Colorless liquid

Use

Reagent in organic synthesis

Reactivity

Highly reactive alkylating agent

Applications

Synthesis of pharmaceuticals and complex organic molecules

Safety

Handle with caution and proper safety measures

Upstream product

• 36215-07-3 1-Chloro-3-methoxypropane 
• 54646-36-5 3-methoxypropyl p-toluenesulfonate 
• 36865-41-5 3-bromopropanol methyl ether 
• 1589-49-7 methoxypropanol 

Downstream Products

• 66897-58-3 N-(2-Chloro-benzoyl)-N-(3-methoxy-propyl)-benzenesulfonamide 
• 5084-33-3 6-methoxyhex-1-ene 
• 13179-98-1 1,6-dimethoxyhexane 
• 627-40-7 methylallylether 
• 866584-85-2 4-methoxy-1-(4-nitrophenyl)butan-1-one 
• 605660-77-3 5-(4-aminophenyl)-6-(2-methoxyethyl)thieno[2,3-d]pyrimidin-4-amine 
• 865156-55-4 4-bromo-2-(3-methoxypropoxy)pyridine 
• 895240-78-5 4-bromo-3-(3-methoxy-propoxy)-benzoic acid methyl ester 
• 895240-72-9 3-(3-methoxy-propoxy)-4-methyl-benzoic acid methyl ester 
• 1187941-43-0 C₃₃H₅₇N₃O₉S 
• 1020734-59-1 1-fluoro-3-[(3-methoxypropyl)sulfonyl]benzene 
• 2046-33-5 3-methoxypropylbenzene 
• 59117-58-7 3-(4-methoxyphenyl)propyl methyl ether 
• 51112-70-0 2-(3-methoxypropyl)cyclohexan-1-one 

Relevant academic research and scientific papers

Regio- And Stereoselective Synthesis of Multi-Alkylated Allylic Boronates through Three-Component Coupling Reactions between Allenes, Alkyl Halides, and a Diboron Reagent

Multisubstituted allylic boronates are attractive and valuable precursors for the rapid and stereoselective construction of densely substituted carbon skeletons. Herein, we report the first synthetic approach for differentially 2,3,3-trialkyl-substituted allylic boronates that contain a stereodefined tetrasubstituted alkene structure. Copper(I)-catalyzed regio- and stereoselective three-component coupling reactions between gem-dialkylallenes, alkyl halides, and a diboron reagent afforded sterically congested allylic boronates. The allylboration of aldehydes diastereoselectively furnished the corresponding homoallylic alcohols that bear a quaternary carbon. A computational study revealed that the selectivity-determining mechanism was correlated to the coordination of a boryl copper(I) species to the allene substrate as well as the borylcupration step.

Diastereoselective Intramolecular Hydride Transfer under Br?nsted Acid Catalysis

A diastereoselective hydride transfer process has been developed under Br?nsted acid-catalyzed reaction conditions using methyl ethers or acetals as hydride donors and tertiary alcohols or alkenes as precursors of carbocation. The method enables construction of complex molecules having multiple stereogenic centers from rather simple and readily available starting materials with predictable diastereoselective control.

ALKOXY BIS-HETEROARYL DERIVATIVES AS MODULATORS OF PROTEIN AGGREGATION

The present invention relates to certain bis-heteroaryl compounds, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease with dementia, fronto-temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer including melanoma.

IMIDAZO[1,2-a]PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES

The present invention relates to novel imidazo[1,2-a]pyrazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which are useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases.

IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS

The present invention relates to novel imidazo[1,2-b]pyridazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which are useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases.

IMIDAZO [1, 2 -A] PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES

The present invention relates to novel imidazo[1,2-a]pyrazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which are useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases.

IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS

The present invention relates to novel imidazo[1,2-b]pyridazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which are useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases.

Enantioselective synthesis of cyclic ethers through a vanadium-catalyzed resolution/oxidative cyclization

(Chemical Equation Presented) Two steps, one catalyst: A vanadium(v)-oxo complex with a tridentate Schiff base as an additional ligand catalyzes the title reaction which transforms racemic bishomoallylic α-hydroxyesters into trans-tetrahydropyrans (THPs)